Coronavirus Update: White House Picks Five Vaccines For US Operation Warp Speed
Fauci Cautiously Optimistic About 2020 Goal
An official announcement is expected within weeks, as competition between US and China stokes fears of 'vaccine nationalism'.
You may also be interested in...
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.